Aptar Active Material Science has launched its Activ-Film technology with a capsule-based Dry Powder Inhalation (DPI) drug product. The solution leverages Aptar’s technology to help safeguard the drug and support product performance throughout shelf life.
The launch marks Aptar’s first commercialization of Activ-Film technology for use with a dry powder inhalation system, building on past FDA approvals of oral solid dosage drugs, implants, and diagnostic products that incorporate this technology.
Badre Hammond, VP of Commercial Operations and general manager at Aptar Active Material Science, says: “The launch of a capsule-based DPI with our Activ Film technology marks a milestone in Aptar’s mission to drive use of material science to advance drug delivery performance and patient experience.”
High performance throughout shelf life
Activ-Film technology uses the company’s 3-Phase Activ-Polymer platform, which is said to offer various customized and highly engineered materials, deployed in a range of configurations. For this launch, Aptar’s Activ-Film material is integrated into the blister packaging that houses the DPI’s dry-powder capsules.
“In this configuration, a piece of custom-engineered Activ-Film material is sealed in an aluminum blister cavity with a channel connecting it to the drug product,” says Aptar Active Material Science.
The design allows the properties of the Activ-Film material to control the microclimate inside the drug blister cavity without coming into contact with the drug capsule itself.
Aptar’s Activ-Polymer technology is developed to assist pharmaceutical partners in meeting drug-specific long-term and in-use stability requirements while supporting therapeutic performance. The solution aims to maintain stability, mitigate degradation and impurities risk, and reinforce overall drug product integrity.
Recently, Aptar Active Material Science secured a US patent for its N-Sorb technology to reduce nitrosamine impurities associated with packaging pharmaceuticals.
Last month, Aptar Pharma announced a system-level data package for injectable drug delivery systems to aid customers in making “more informed” development decisions. In collaboration with its partners, the data package combines system-level testing and performance data, such as container closure integrity and sealing requirements, for injectable therapies.
Last year, Aptar CSP Technologies opened a medical packaging facility in New Jersey, US. The new site enables the pharma pack provider to expand its service offerings to cGMP-compliant manufacturing.
Source: packaginginsights.com
A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences. Amsterdam-based argenx agreed to buy Forte in July to acquire FB102, an anti-CD122 antibody that hit the mark in a phase 1b vitiligo trial weeks before the deal.
Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, US. Building on more than seven billion dollars in US pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy.
Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility in the UK, which will double capacity, as well as increasing the scale of manufacturing to 500L.
